Novartis - Entity Dossier | Plocamium Intelligence

Novartis

ORG Health Care / Pharmaceuticals Momentum 11.2 NORMAL Primary: Spectral Shift

$95B market cap (Basel) pharmaceutical giant pulled EU label expansion for Pluvicto prostate cancer therapy while securing WHO prequalification for antimalarial combination drug targeting pediatric populations. Recent signals show regulatory retreat in oncology offset by infectious disease validation.

Withdrew Pluvicto prostate cancer label expansion filing in EU; malaria drug received WHO prequalification; domestic US industrial partnerships with Nucor and US Forged Rings.

-0.33

PSI Score

11.2

Momentum

Confidence

Connections

PSI Intelligence

30-Day Trend

Signal Decomposition

Attention Cascade

-0.000

Narrative Drift

0.000

Spectral Shift

414.669

Sentiment-Momentum Divergence

0.000

Source Concentration

0.878

Peer Comparison

N/A

Sector Rank

+0.00

Peer Z-Score

Sector Percentile

Network Analysis

10 Degree Centrality

Centrality History

Entity	Weight	Status
Merck	52	STRENGTHENED
Pfizer	52	STRENGTHENED
United States	7	STABLE
European Union	5	STABLE
Anthropic	4	STABLE
China	3	STABLE
Senator	2	NEW
Texas	2	STABLE
DOD	2	STABLE
CEO	2	STABLE
AstraZeneca	2	NEW
Airbus	2	NEW
Barclays	2	NEW
Ohio	1	NEW
Massachusetts	1	NEW
WHO	1	STABLE

Article Coverage (0)

Date	Lane	Title

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.